IGF-1 and Macrovascular Complications of Diabetes
Alternative interpretations of recently published data
- Elena Conti, MD1,
- Dario Pitocco, MD2,
- Ettore Capoluongo, BSC, PHD3,
- Cecilia Zuppi, MD3,
- Giovanni Ghirlanda, MD2,
- Filippo Crea, MD, FESC, FACC1 and
- Felicita Andreotti, MD, PHD, FESC1
- 1Department of Cardiology, Catholic University, Rome, Italy
- 2Department of Diabetologia, Catholic University, Rome, Italy
- 3Department of Hormonal Chemistry, Rome, Italy
The hypothesis of a detrimental role for IGF-1 and other growth factors in the development of vascular disease (1) has not been consistently supported by recent studies (2,3). New evidence suggests that cellular senescence (4) and impaired vascular endothelial proliferation, adhesion, and incorporation play a pivotal role in the development of macrovascular
disease (5). Indeed, recent data on large numbers suggest that higher IGF-1 bioavailability may protect against the onset of ischemic
heart disease (6,7) and glucose intolerance (8) and, in type 2 diabetic patients, may offer improved metabolic control and prevent vascular complications (9,10). Other potential beneficial actions of IGF-1 in cardiovascular physiology include increased nitric oxide synthesis and K+ channel opening (11,12), and this may explain the impaired small-vessel function associated with low IGF-1 levels in patients with cardiovascular
syndrome X (12). By counteracting oxidized LDL-induced cytotoxicity and vascular smooth muscle cell apoptosis, IGF-1 may protect against
plaque instability and rupture (2). In patients with acute myocardial infarction, markedly reduced IGF-1 values are associated with a worse outcome (13,14), and recent data suggest that intramyocardial (15,16) or vascular (17) gene delivery of growth factors can improve symptoms and exercise capacity in patients with coronary or peripheral vascular
disease.
We were therefore surprised by two recent studies proposing IGF-1 as a mediator of harmful vascular effects (18,19). The authors found an inverse association between IGF binding protein (IGFBP)-1 and carotid intimal-medial thickness (r = −0.135, P = 0.041) (18), macrovascular disease (19), and hypertension (19) in patients with type 2 diabetes. IGFBP-1 is a minor component of the system of IGFBPs 1–6, first discovered in the 1990s,
and regulated by a complex group of proteases and phosphatases (20). As IGFBP-1 is generally assumed to inhibit IGF-1 bioavailability (21), the authors conclude that IGF-1 exerted harmful vascular effect (18,19).
We propose two different interpretations of the above data, not necessarily exclusive. First, the reduced IGFBP-1 concentration
observed in situations of vascular disease (18,19) could result from activation of a compensatory mechanism leading to higher IGF-1 bioavailability. This interpretation is
confirmed by the finding in hypertensive patients of higher IGF-1 levels than in control subjects (22), and of a positive association among IGF-1, insulin sensitivity, and preserved vasodilator capacity (23,24). Indeed, in these patients, IGF-1 was the main independent predictor of both coronary reserve and insulin sensitivity (23). Second, alternatively or additionally, one should consider that the interaction between IGF-1 and its binding proteins
is complex. An adequate serum amount of total IGFBP-1 is essential for IGF-1’s biological activity (8,25), independently of its phosphorilation status. Moreover, overexpression of IGFBP-1 attenuates IGF-1’s growth-promoting actions
in vitro but enhances them in vivo (26). Thus, a threshold concentration of IGFBP-1 might enhance, rather than impair, IGF-1’s bioactivity through a partial agonism-like
action.
Because IGFBPs have been characterized only recently and their physiology in humans is not completely understood, we think
further studies are needed to better understand the true value of the IGF-1/IGFBP axis in promoting or protecting against
vascular complications.
Footnotes
-
Address correspondence to Elena Conti, MD, Institute of Cardiology, Catholic University, Via Todi 60, 00181 Rome. E-mail:
e_conti02{at}hotmail.com.
- DIABETES CARE
References
- ↵
Grant MB, Wargovich TJ, Ellis EA, Caballero S, Mansour M, Pepine CJ: Localization of insulin-like growth factor 1 and inhibition
of coronary smooth muscle cell growth by somatostatin analogues in human coronary smooth muscle cells: a potential treatment
for restenosis? Circulation 89:1511–1517, 1994
- ↵
Frystyk J, Ledet T, Moller N, Flyvbjerg A, Orskov H: Cardiovascular disease and insulin-like growth factor 1. Circulation 106:893–895, 2002
- ↵
Janssen JA, Lamberts SWJ: The role of IGF-1 in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention
possible? Eur J Endocrinol 146:467–477, 2002
- ↵
Erusalimsky JD, Fenton M: Further in vivo evidence that cellular senescence is implicated in vascular pathophysiology (Letters).
Circulation 106:e144, 2002
- ↵
Tepper OM, Galiano RD, Capla JM, Kalka C, Gagne PJ, Jacobowitz GR, Levine JP, Gurtner GC: Human endothelial progenitor cells
from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781–2786, 2002
- ↵
Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T: Low serum insulin-like growth factor 1 is associated with increased
risk of ischemic heart disease: a population-based case control study. Circulation 106:939–944, 2002
- ↵
Conti E, Crea F, Andreotti F: IGF-1 and risk of ischemic heart disease. Circulation. In press
- ↵
Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ: Circulating concentrations of insulin-like growth factor-1
and development of glucose intolerance: a prospective observational study. Lancet 359:1740–1745, 2002
- ↵
Garay-Sevilla ME, Nava LE, Malacara JM, Wrobel K, Perez U: Advance glycosylation end products (AGEs), insulin-like growth
factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 16:106–113, 2000
- ↵
Janssen JAMIL, Lamberts SWJ: Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clinical Endocrinology 52:1–9, 2000
- ↵
Muniyappa R, Walsh MF, Rangi JS, Zayas RM, Standley PR, Ram JL: Insulin-like growth factor 1 increases vascular smooth muscle
nitric oxide production. Life Science 61:925–931, 1997
- ↵
Conti E, Andreotti F, Sestito A, Riccardi P, Menini E, Crea F, Maseri A, Lanza GA: Markedly reduced insulin-like growth factor-1
associated with insulin resistance in syndrome X patients. Am J Cardiol 89:973–975, 2002
- ↵
Conti E, Andreotti F, Sciahbasi A, Riccardi P, Marra G, Menini E, Ghirlanda G, Maseri A: Markedly reduced insulin-like growth
factor-1 in the acute phase of myocardial infarction. J Am Coll Cardiol 38:26–32, 2001
- ↵
Friberg L, Werner S, Eggertsen G, Ahnve S: Growth hormone and insulin-like growth factor-1 in acute myocardial infarction.
Eur Heart J 21:1547–1554, 2000
- ↵
Stewart DJ, on behalf of the REVASC Study Investigators: A phase 2, randomized, multicenter, 26-week study to assess the efficacy
and safety of BIOBYPASS (AdGVVEGF121,10) delivered through minimally invasive surgery versus maximum medical treatment in
patients with severe angina, advanced coronary artery disease, and no options for revascularization (Abstract). Circulation 106:2986, 2002
- ↵
Losordo DW, Kawamoto A: Biological revascularization and the interventional molecular cardiologist: bypass for the next generation.
Circulation 106:3002–3005, 2002
- ↵
Vale PR, Isner JM, Rosenfield K: Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol 14:511–528, 2001
- ↵
Leinonen ES, Salonen JT, Salonen RM, Koistinen RA, Leinonen PJ, Sarna SS, Taskinen MR: Reduced IGFBP-1 is associated with
thickening of the carotid wall in type 2 diabetes. Diabetes Care 25:1807–1812, 2002
- ↵
Heald AH, Siddals KW, Fraser W, Taylor W, Kaushal K, Morris J, Young RJ, White A, Gibson JM: Low circulating levels of insulin-like
growth factor binding protein-1 (IGFBP-1) are closely associated with the presence of macrovascular disease and hypertension
in type 2 diabetes. Diabetes 51:2629–2636, 2002
- ↵
Baxter RC: Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab 278:E967–E976, 2000
- ↵
Schneider MR, Lahm H, Wu M, Hoeflich A, Wolf E: Transgenic mouse models for studying the functions of insulin-like growth
factors. FASEB J 14:629–640, 2000
- ↵
Galderisi M, Vitale G, Lupoli G, Barbieri M, Varricchio G, Carella C, de Divitiis O, Paolisso G: Inverse association between
free insulin-like growth factor-1 and isovolumic relaxation in arterial systemic hypertension. Hypertension 38:240–245, 2001
- ↵
Galderisi M, Caso P, Cicala S, De Simone L, Barbieri M, Vitale G, de Divitiis O, Paolisso G: Positive association between
circulating free insulin-like growth factor-1 levels and coronary flow reserve in arterial systemic hypertension. Am J Hypertens 15:766–772, 2002
- ↵
Laviades C, Gil MJ, Monreal I, Gonzalez A, Diez J: Tissue availability of insulin-like growth factor I is inversely related
to insulin resistance in essential hypertension: effects of angiotensin converting enzyme inhibition. J Hypertens 16:863–870, 1998
- ↵
Shinobe M, Sanaka T, Nihei H, Nobuhiro S: IGF-1/IGFBP-1 as an index for discrimination between responder and nonresponder
to recombinant human growth hormone in malnourished uremic patients on hemodialysis. Nephron 77:29–36, 1997
- ↵
Modric T, Rajkumar K, Murphy LJ: Thyroid gland function and growth in IGF binding protein-1 transgenic mice. Eur J Endocrinol 141:149–159, 1999
